Interferon-Tau
Also known as: IFN-τ, Trophoblast Interferon, Ovine interferon-tau
Overview
Interferon-tau (IFN-τ) is a unique type I interferon produced by the trophoblast cells of ruminants during early pregnancy. Unlike other type I interferons (α, β), IFN-τ exhibits potent immunomodulatory and anti-inflammatory properties at doses that do not cause the fever, flu-like symptoms, or toxicity typical of IFN-α therapy. Oral IFN-τ has been investigated for autoimmune diseases including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, with the interesting property that mucosal (oral) administration avoids systemic toxicity while maintaining immunomodulatory efficacy.
Mechanism of Action
IFN-τ binds type I interferon receptors (IFNAR1/IFNAR2) and activates JAK1/TYK2 kinase signaling, leading to STAT1 and STAT2 phosphorylation and formation of the ISGF3 transcription factor complex that drives interferon-stimulated gene (ISG) expression. The anti-inflammatory rather than antiviral skewing of IFN-τ compared to IFN-α may relate to differential receptor binding kinetics and distinct downstream gene expression programs. Oral delivery to intestinal lymphoid tissue induces local immune tolerance programs that propagate systemically without high systemic cytokine levels.
Potential Benefits
- Immunomodulation without classical interferon toxicity
- Potential treatment for autoimmune diseases (MS, RA, lupus)
- Oral administration viable (unlike IFN-α)
- Anti-inflammatory in models of experimental autoimmune encephalomyelitis
- Reduced relapse rate in MS pilot studies
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | Not a clinical human peptide |
| Intermediate | N/A |
| Advanced | N/A |
| Cycle Duration | Research-defined |
Ruminant-specific Type I interferon (ovine/bovine reproduction). Low-dose oral use studied for MS, HIV, immune modulation.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Oral mucosal (low dose) Local mucosal effect; systemic low
Main research route — buccal/oral lozenge delivery.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving Interferon-Tau:
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate at 2-8°C after reconstitution. Do not freeze reconstituted solution. |
|---|
Typical vial sizes: Research-grade lyophilized protein. Add bac water slowly down the side of the vial, swirl gently — do not shake. Use insulin syringe for precise dosing.
Need exact syringe measurements?
Amino Acid Sequence
172 AA protein (ruminant trophoblast interferon)
Side Effects & Safety
- Oral administration: minimal systemic effects at therapeutic doses
- Potential immune dysregulation at high doses
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | Not well characterized for this peptide; consult primary literature |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside Interferon-Tau for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.